Printer Friendly


Advanced Biological Laboratories (ABL) S.A. has signed a contract with the Spanish Association for the Study of the Liver (Asociacion para el Estudio del Hidago, AEEH) for the development and licensing of the new HepatiC software and database system.

ABL undertakes the development, maintenance and upgrades and provides national access to the HepatiC program to the Spanish Community of Hepatologists to aid in the optimal personalized management of their HCV patients, especially those being treated with Direct Acting Antiviral (DAA) therapy.

"The HepatiC initiative in Spain will facilitate the creation of a national HCV patient Registry and Database", stated Pr Esteban, Head of the Internal Medicine and Hepatology Department, Hospital Vall d'Hebron in Barcelona. "This tool is key to the support of our epidemiological studies, the monitoring of patient outcomes and the reporting to regional, national and international institutions".

The design and scientific content of HepatiC was directed by Spanish key opinion leaders and experts. The ABL experienced team ensures the development, the implementation and maintenance of the HepatiC system.

ABL is also in charge of the HepatiC commercialization outside Spain and undertakes to provide HepatiC to the largest community of physicians treating HCV-infected patients. "We are honoured to be working with the AEEH and the Spanish experts on liver diseases and to share our respective knowledge with them" said Dr Sayada, ABL CEO. "HepatiC shall reinforce ABL business in viral hepatitis, infectious diseases and oncology in the near future, in several continents".

About ABL

Advanced Biological Laboratories (ABL), S.A., is a biotech company founded in 2000 as a spin-off from the European academic research center, CRP-Sante Luxembourg and in 2004, acquired the control of TherapyEdge, Inc, a biotech company spin-off from Triangle Pharmaceuticals, Inc. and in 2013 acquired the Viral Hepatitis B & C related assets from EVIVAR MEDICAL, a biotech company spin-off from Melbourne Health in Australia. ABL has a comprehensive suite of healthcare management tools, including TherapyEdge, ViroScore, SeqHepB, DeepChek, VisibleChek and HepatiC, which are used for data and patient management, monitoring and personalized reporting applications. In 2012, ABL's products received respectively CE-marking and IVD certifications. ABL's products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions, for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems combining standard and high- throughput Next Generation Sequencing data. The clinical and biological outcomes aid in the generation of clinically meaningful genotyping reports for personalized healthcare.

For more information, visit or call +352 2638 8921.
COPYRIGHT 2013 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Databases
Date:Nov 1, 2013

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters